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Abstract
Background: Liver cirrhosis is the fourth cause of death in adults in Western countries, with complications of portal
hypertension being responsible for most casualties. In order to reduce mortality, development of accurate diagnostic
methods for early diagnosis, effective etiologic treatment, improved pharmacological therapy for portal hypertension,
and effective therapies for end-stage liver failure are required.
Discussion: Early detection of cirrhosis and portal hypertension is now possible using simple non-invasive
methods, leading to the advancement of individualized risk stratification in clinical practice. Despite previous
assumptions, cirrhosis can regress if its etiologic cause is effectively removed. Nevertheless, while this is now
possible for cirrhosis caused by chronic hepatitis C, the incidence of cirrhosis due to non-alcoholic steatohepatitis has
increased dramatically and effective therapies are not yet available. New drugs acting on the dynamic component of
hepatic vascular resistance are being studied and will likely improve the future management of portal hypertension.
Conclusion: Cirrhosis is now seen as a dynamic disease able to progress and regress between the compensated and
decompensated stages. This opinion article aims to provide the author’s personal view of the current major advances
and challenges in this field.
Keywords: Hepatic venous pressure gradient, Non-invasive methods, Liver stiffness, Therapy, Transjugular intrahepatic
portosystemic shunt
Background
Chronic liver disease (CLD) affects more than 29 million
people in Europe [1] and over 300 million people world-
wide. The main causes of CLD are alcohol abuse, chronic
viral hepatitis, and metabolic factors (non-alcoholic fatty
liver disease). Over time, extracellular fibrotic tissue de-
velops and accumulates in the liver as a result of chronic
injury, progressively leading to fibrous septa that prevent
normal oxygenation and blood exchange to the liver par-
enchyma. This late stage, featuring marked liver anatom-
ical changes, including hepatocyte extinction, micro- and
macrovascular remodeling, neoangiogenesis, nodule for-
mation, and development of portosystemic shunts, is
termed ‘cirrhosis’ [2]. Mortality in CLD is primarily due to
complications of liver cirrhosis and hepatocellular carcin-
oma (HCC), which is considerably more prevalent in pa-
tients with cirrhosis. The term ‘advanced chronic liver
disease’ (ACLD) has been recently proposed to better mir-
ror the late stages of CLD, which should be considered
within a continuum spectrum, ranging from severe fibro-
sis to fully developed cirrhosis [3].
Compensated versus decompensated cirrhosis:
the burden of advanced chronic liver disease
(ACLD)
According to the largest study available thus far [4],
cirrhosis represents the fourth cause of death due to
non-communicable diseases worldwide, with the total
number of deaths from cirrhosis and liver cancer having
steadily risen by approximately 50 million per year over
the last two decades. This large mortality rate is due, to
some extent, to a late diagnosis. A decades-long asymp-
tomatic stage during which no overt sign of the disease
is noticed is characteristic of CLD. Indeed, even after the
onset of cirrhosis, the disease can remain
asymptomatic, or ‘compensated’, for a long time [5].
Nevertheless, during this time, portal hypertension
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progressively develops, usually accompanied by a
decline in hepatocellular function.
Portal hypertension is the major driver in the transi-
tion from the compensated to the ‘decompensated’ stage
of cirrhosis [5], defined by the presence of clinical com-
plications, including ascites [6], bleeding from gastro-
esophageal varices [7], spontaneous bacterial peritonitis
[8], hepatorenal syndrome [6], and hepatic encephalop-
athy [9]. Further decompensating episodes are often trig-
gered by bacterial infections [10], and are associated
with a very high mortality risk. From a prognostic point
of view, compensated and decompensated cirrhosis are
dramatically different, and can be considered as two sep-
arate diseases. Furthermore, within these two major
stages, several sub-stages with varying risk of further de-
compensation and death can be identified [11] (Fig. 1).
Knowledge of the pathophysiological mechanisms driv-
ing the transition within these stages is key in the
current management of cirrhosis [7]. Besides its negative
impact on life expectancy, cirrhosis implies several other
burdens, including a marked increase in healthcare costs
due to hospitalization and treatment (estimated at ap-
proximately $2.5 billion per year in the US) [12], loss of
productivity (estimated at $10.6 billion per year in the
US) [12], and a marked reduction in quality of life [13].
These burdens are almost exclusively caused by compli-
cations during the decompensated stage.
Given that chronic viral hepatitis C (HCV) is a leading
etiology of CLD [14], the recent availability of direct, high
efficacy oral antiviral agents against HCV represents a
major breakthrough towards achieving a reduction in
mortality linked to CLD. Unfortunately, despite the reduc-
tion in the incidence of HCV-related liver disease compli-
cations already observed [15] and the marked decrease
further expected over the coming years, over 40% of HCV
infection cases have not been identified and may be recog-
nized at a late, decompensated stage, when treatment of
the viral infection may be futile [16]. In addition, other eti-
ologies of CLD are becoming more common or remaining
steadily frequent. Cirrhosis due to non-alcoholic steatohe-
patitis is markedly increasing as a consequence of the
obesity pandemic worldwide [17], already ranking sec-
ond among the etiologies of cirrhosis in patients on the
waiting list for liver transplantation in the US [15].
Furthermore, liver disease associated with alcohol use
disorders is highly prevalent worldwide, and is particu-
larly relevant in Europe, where it accounts for the high-
est proportion of cirrhosis cases [18]. Of note, over the
past 30 years, mortality due to cirrhosis in Europe
increased in areas with the highest alcohol consump-
tion (United Kingdom, Eastern Europe, Ireland, and
Finland) [19]. Nevertheless, in several countries within
the EU limiting alcohol use is not yet considered an
absolute priority for policy-makers [20].
Over the last decades, new knowledge on the patho-
physiology, diagnostic methods, and therapy of cirrhosis
and portal hypertension have significantly improved the
management of this disease, with a marked reduction in
mortality related to some of its complications, particu-
larly variceal bleeding [21]. However, in a recent analysis
based on over 100,000 cases, 30-day mortality following
discharge for any decompensation of cirrhosis was equal
to or even higher than that observed 10 years prior, sug-
gesting that the burden of mortality was merely shifted
to the immediate postdischarge period [22]. Among the
major determinants of mortality are inflammation in
acute-on-chronic liver failure (associated with different
complications of end-stage liver disease) and HCC
[23] (not discussed in the present paper), both of which
have been the subject of extensive research but remain
unsatisfactorily resolved.
To achieve a substantial improvement in survival,
every step of the management process of patients with
ACLD should be addressed and optimized (Fig. 2). An
early diagnosis of cirrhosis, i.e., within the compensated
stage, and an accurate risk stratification are key to the
following steps. Indeed, in the author’s opinion, the use
of resources at this initial step (e.g., initiation of HCC
surveillance, endoscopic screening of varices needing
treatment in patients at high risk, prevention of decom-
pensation by appropriate non-pharmacological and
pharmacological therapy) is largely justified by the ex-
pected survival benefits.
Early diagnosis and risk stratification: moving
towards personalized medicine
The reference standard methods to diagnose cirrhosis,
portal hypertension, and esophageal varices are liver bi-
opsy, hepatic venous pressure gradient (HVPG) measure-
ment, and endoscopy, respectively [24]. All of these
methods are invasive, and require expertise to be correctly
performed and interpreted. Undoubtedly, the availability
of novel non-invasive diagnostic methods, and ultrasound
elastography in particular, has enhanced the likelihood of
early diagnosis of ACLD, facilitating the identification of
patients with compensated disease who are at high risk of
complications, prior to the occurrence of decompensation.
Liver stiffness (and more recently spleen stiffness) can be
measured by various ultrasound elastography methods
[25], and mirrors the severity of liver disease and portal
hypertension in patients with compensated ACLD [26].
The diagnosis of clinically significant portal hypertension
(CSPH; HVPG ≥ 10 mmHg) is made possible by elastogra-
phy, with an accuracy greater than 80% when using a bin-
ary cut-off approach [27]. As with all numerical variables
holding prognostic value, liver stiffness can be modeled
and calibrated, and the risk (probability) of CSPH can be
calculated according to the measured values [28], thus
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leading to personalized medical decision-making. The vast
data available regarding the relationship between liver
stiffness, CSPH, and varices led the Baveno VI consensus
conference on portal hypertension, held in 2015 [29], to
suggest a simple combination of liver stiffness measured
by transient elastography (<20 kPa) and platelet count
(>150 G/L) in order to identify patients at low risk of vari-
ces needing treatment in whom endoscopic screening
could be safely avoided [29]. Since 2015, these non-
invasive criteria have proven robust and accurate, even if
conservative (only approximately 20–25% of endoscopies
spared). Recent research has proposed expanded non-
Fig. 1 Clinical stages of cirrhosis. The first major classification is based on the absence or presence of complications. Cirrhosis is named ‘compensated’
in the absence of complications, and ‘decompensated’ if complications are present or have been present in the past. In patients with compensated
cirrhosis, the presence of clinically significant portal hypertension (HVPG ≥ 10 mmHg) identifies a substage with higher risk of developing
any complication (varices, decompensation). The decompensated stage is characterized by a high risk of progression to further decompensation, liver
failure, and death. Evidence-based therapy has been developed by targeting the pathophysiological mechanisms driving the transition from a given
step to the following one. The major advances in each stage are indicated within the figure
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invasive criteria allowing a much larger proportion of en-
doscopies to be spared without increasing the risk of false
negative results [30, 31].
Real-time, simple diagnostic methods, such as ultra-
sound and elastography, are key to achieving bedside
screening and first risk stratification. However, in patients
who cannot be sufficiently characterized by these simple
methods or in particularly sensitive situations, such as in
patients with compensated cirrhosis and potentially re-
sectable HCC [23, 32], HVPG measurement remains the
best method to accurately stage portal hypertension.
Nevertheless, recent advances in magnetic resonance im-
aging (magnetic resonance elastography [33], multipara-
metric magnetic resonance imaging [34]) hold promise
and should be further investigated as surrogates of portal
hypertension, particularly in patients who are not appro-
priate candidates for ultrasound elastography.
Despite the use of diagnostic tests being of paramount
importance to achieve a correct risk stratification, the
meaning of risk factors that are easily detected by phys-
ical examination and clinical history should not be disre-
garded. For instance, factors related to nutrition, and
which are therefore potentially modifiable, should be ac-
tively investigated. Irrespective of the etiology leading to
ACLD, overweight and obesity are increasingly observed
in compensated patients [35], and have been consistently
associated with an up to three-fold higher risk of clinical
decompensation. Further, sarcopenia [36] and vitamin D
deficiency [37] are frequent in cirrhosis (including in
obese patients), almost invariably present in decompen-
sated patients, and associated with higher mortality. Re-
search in the field of nutritional factors modulating the
natural history of cirrhosis is insufficient and represents
a field for future investigation. For example, while
alcohol intake is a well-known negative prognostic
factor, coffee consumption has only recently been
proven protective [38, 39].
Future research should also focus on providing accur-
ate and individualized prediction of ‘hard’ endpoints,
such as clinical decompensation and death, by non-
invasive diagnostic methods. In the author’s opinion, the
development of risk algorithms similar to those used in
cardiovascular medicine (e.g., Framingham risk score
[40]) would be advisable and feasible in the field of com-
pensated cirrhosis to predict and stratify the risk of com-
plications of portal hypertension.
Advances in therapy
Several studies have demonstrated that, in portal hyper-
tensive patients, if portal pressure is reduced enough
(i.e., by at least 20%) by applying pharmacological and/or
non-pharmacological therapies, the risk of decompensa-
tion or further decompensation and death is markedly
reduced [7, 41–43] – this constitutes the rationale of
treatment of portal hypertension. To achieve the highest
efficacy, treatment should be aimed at correcting the
main pathophysiological target in each stage of cirrhosis.
In the early, compensated stages of cirrhosis, increased
hepatic resistance plays a pivotal role in the development
of portal hypertension (Pressure = Resistance × Flow) [2].
Therefore, in compensated cirrhosis, correction of in-
creased intrahepatic resistance should be addressed [7, 44].
This can be achieved by ameliorating the mechanical com-
ponent of resistance mostly represented by fibrosis and/or
by acting on the functional component represented by ac-
tive vasoconstriction and sinusoidal endothelial dysfunction
Fig. 2 Logical steps in the clinical management of advanced chronic liver disease/cirrhosis. Improved survival can be achieved through adequate
diagnosis and risk stratification, thus allowing a personalized approach to therapy. Some examples of factors to be considered, as well as
the major pathophysiological factors driving the therapy of portal hypertension in patients with compensated cirrhosis, are provided
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[45]. Etiologic treatments have been shown effective in im-
proving fibrosis and can lead to cirrhosis regression in the
long term [46]; thus, they should be considered central at
this stage of the disease.
Short-term (4 months) lifestyle changes consisting of
diet and exercise combinations are able to improve obes-
ity in compensated cirrhosis and are associated with a
significant reduction in HVPG [47], likely mirroring a
decrease in intrahepatic resistance (e.g., mediated by a
decrease in insulin resistance). While supplementing
vitamin D deficiency and correcting sarcopenia is likely
to positively influence prognosis, the mechanisms driv-
ing the interaction between nutritional factors and portal
hypertension remain to be elucidated.
Pure antifibrotic drugs are currently lacking [48]. How-
ever, statins, which improve the phenotype of sinusoidal
endothelial cells by restoring nitric oxide production, are
able to decrease intrahepatic fibrogenesis and angiogenesis
in experimental models [49] and ameliorate portal hyper-
tension by decreasing both the dynamic and structural
components of intrahepatic resistance [50]. Interestingly,
this is accompanied by an amelioration in hepatic function
and perfusion in patients with cirrhosis [51]. Statins have
proven effective in preventing hepatic decompensation in
large epidemiological surveys in patients with HCV and
hepatitis B virus cirrhosis [52, 53]. In addition, their use has
been associated with a decreased risk of HCC [54] and,
most recently, addition of simvastatin to standard medical
and endoscopic therapy has been shown to improve sur-
vival in a double-blind randomized multicenter clinical trial
in patients who survived an episode of bleeding from
esophageal varices [55]. Thus, statins constitute the most
promising class of drugs to be added to the standard ther-
apy armamentarium for ACLD and portal hypertension.
Once CSPH has developed, and even more so following
the formation of varices, the resulting hyperdynamic cir-
culatory state leads to an increased portocollateral flow,
which aggravates portal hypertension [2, 56]. At this stage,
drugs acting to reduce blood flow are effective in reducing
portal pressure. Non-selective beta-blockers (NSBBs; pro-
pranolol, nadolol, or carvedilol) are the mainstay of ther-
apy in this clinical scenario [7], and recent data from a
randomized controlled trial (RCT) suggest that they
effectively reduce the risk of ascites and clinical decom-
pensation in patients with small varices [57].
Given the abovementioned data, it has been suggested
that NSBBs, statins, and oral antibiotics (rifaximin [58] or
norfloxacin) could be used in combination to prevent clin-
ical decompensation in patients with cirrhosis [59]. In a
recent study, patients treated with rifaximin added to pro-
pranolol showed a more marked decreased in HVPG as
compared to patients on propranolol alone [60].
A further group of drugs showing promising results is
represented by anticoagulants. Contrarily to what was
previously thought, cirrhosis can be considered a pro-
coagulant state, and experimental data suggest that
low molecular weight heparin [61] and direct oral an-
ticoagulants [62] inhibit fibrogenesis and decrease
portal pressure in cirrhosis. A small RCT using enox-
aparin to prevent portal vein thrombosis in patients
in the waiting list for liver transplantation showed a
reduction in mortality [63].
Given the increased susceptibility to life-threatening
bacterial infections observed in patients with decompen-
sated cirrhosis [8], the reduction of intestinal bacterial
translocation by antibiotic therapy is another potential
treatment able to reduce the risk of spontaneous bacter-
ial peritonitis and mortality in patients with decompen-
sated cirrhosis and ascites. In a recent RCT [64],
norfloxacin combined to standard medical therapy im-
proved survival compared with standard medical therapy
alone in patients with decompensated alcoholic cirrhosis
and severe liver failure. In addition, a further strategy
aimed at improving effective intravascular volemia by
using weekly administration of intravenous albumin in
addition to standard medical therapy improved survival
in patients with ascites versus standard medical therapy
alone [65]. Nevertheless, these results are not yet pub-
lished in full and require validation.
Transjugular intrahepatic portosystemic shunt (TIPS)
is a well-accepted therapy to prevent rebleeding in pa-
tients experiencing more than one episode of variceal
bleeding, in patients with refractory ascites it demon-
strated a survival benefit vs. large volume paracentesis.
Recent data suggest that TIPS may also be applied to
other clinical scenarios in cirrhosis to improve out-
comes. In a RCT of TIPS versus standard medical plus
endoscopic therapy in patients presenting with variceal
bleeding and poor liver function (Child–Pugh score B9
to C12 points), the early use of TIPS (within 72 hours
with the aim of preventing early rebleeding) reduced
mortality by 25% [66]; these results have been validated
in a second multicentric study [67]. In the setting of
patients with recurrent (not refractory) ascites, TIPS
improved survival by over 40% in comparison to
standard medical therapy [68].
A major gap remains regarding the ability to non-
invasively monitor the effect of therapy on portal pres-
sure. None of the currently available non-invasive tests
holds sufficient accuracy in mirroring the HVPG re-
sponse. A recent study suggested that changes in spleen
stiffness (measured by point shear wave elastography)
might parallel changes in HVPG and portal pressure gra-
dient after NSBB and TIPS [69]; however, these results
require validation. The development of other non-
invasive tests, such as subharmonic aided pressure esti-
mation on contrast-enhanced ultrasound [70], as well as
non-invasive measurements derived by parameters from
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contrast-enhanced ultrasound [71] or magnetic reson-
ance imaging [34] are urgently needed in this field.
Finally, a novel challenge has resulted with regards to
the population of patients with HCV cirrhosis in whom
the virus was successfully cured by direct acting antivi-
rals. A minority of these patients will improve after
treatment, but a substantial proportion (over 70%) of
those who had CSPH at the time of therapy remains at
risk of developing complications of portal hypertension
[72]. Unfortunately, we currently lack non-invasive sur-
rogates of HVPG in this population, and it remains un-
known whether cirrhosis will successfully revert in the
long term. The ‘point of no return’ in the natural history
of cirrhosis is currently unknown, and certainly repre-
sents a major field for future research as well as a poten-
tial endpoint for novel therapies.
Conclusions and future perspectives
Currently, cirrhosis is considered a dynamic disease able
to progress and regress. In this new way of understanding
the spectrum of changes characterizing ACLD, early diag-
nosis, prior to the occurrence of decompensation, is an
important step to achieve a reduction in mortality due to
CLD since several different pharmacological and non-
pharmacological approaches can be used during this phase
to prevent decompensation (an ominous step in the nat-
ural history of this disease). Ultrasound elastography of
the liver allows an accurate non-invasive identification of
patients with ACLD, with the additional advantage of pro-
viding a numerical surrogate of the risk of portal hyper-
tension and complications. Prevention of decompensation
is possible by reducing portal pressure through measures
aimed at eliminating all the possible sources of injury (eti-
ology and cofactors), at reducing intrahepatic resistance
(e.g., by correcting intrahepatic endothelial dysfunction),
and at reducing portocollateral flow. Long-standing drugs,
such as NSBBs, remain the mainstay for portal pressure
reduction and are able to prevent not only variceal bleed-
ing, but also other more frequent decompensating events
such as ascites. After decompensation, therapy should be
aimed towards avoiding further decompensation and
death, with statins being promising in these cases. TIPS is
effective in decreasing the risk of variceal rebleeding and
improves mortality in patients with recurrent and refrac-
tory ascites. The extent to which modulating the gut
microbiota impacts the natural history of decompensated
cirrhosis remains unknown, yet antibiotics already play an
important role in the prevention and treatment of severe
bacterial infection in decompensated patients. Unfortu-
nately, despite the indubitable improvement in the man-
agement of portal hypertension, severe liver failure cannot
be reversed.
Effective artificial liver support remains a major unmet
need in patients with end-stage liver disease, with liver
transplantation representing the only available curative
option to date (in those who have no contraindications).
Indeed, research in the field of regenerative medicine
represents a major expected breakthrough of the 21st
century, holding great promise [73] for a reduction in
the need of liver transplantation in the future.
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